Sean Michael Smith serves as Executive at Neoleukin Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Sean Michael Smith has executed 6 insider transactions totaling $4.4K, demonstrating a bearish approach to their equity position. Their most recent transaction on Aug 11, 2023 involved selling 1,323 shares valued at $820.
Sean Michael Smith currently holds 21,637 shares of Neoleukin Therapeutics, Inc. (NLTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sean Michael Smith has been a net seller of NLTX stock. They have purchased $0 and sold $4.4K worth of shares.
Sean Michael Smith's most recent insider trade was on Aug 11, 2023, when they sold 1,323 shares at $0.62 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Feb 2, 2023 | NLTX | $2.0K | Sale | 3,316 | $0.60 | Discretionary |
| Feb 1, 2023 | NLTX | $0 | Option Exercise | 12,500 | $N/A | Discretionary |
| Aug 10, 2022 | NLTX | $0 | Option Exercise | 5,000 | $N/A | Discretionary |
| Aug 10, 2022 | NLTX | $1.6K | Sale | 1,655 | $0.99 | Discretionary |